AnaptysBio, Inc. (NASDAQ:ANAB) Receives $54.64 Consensus PT from Analysts

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have been assigned a consensus rating of “Moderate Buy” from the twelve ratings firms that are presently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $54.64.

ANAB has been the topic of a number of recent research reports. Guggenheim boosted their price objective on AnaptysBio from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Wedbush reissued an “outperform” rating and set a $42.00 price target on shares of AnaptysBio in a research report on Thursday, September 26th. HC Wainwright restated a “buy” rating and set a $55.00 price objective on shares of AnaptysBio in a research report on Wednesday, August 14th. JPMorgan Chase & Co. boosted their target price on shares of AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Finally, Truist Financial raised their price target on shares of AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a report on Thursday, August 15th.

Insiders Place Their Bets

In other news, insider Paul F. Lizzul sold 1,500 shares of AnaptysBio stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total value of $58,005.00. Following the completion of the sale, the insider now directly owns 15,398 shares of the company’s stock, valued at approximately $595,440.66. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, insider Paul F. Lizzul sold 1,500 shares of the firm’s stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $38.67, for a total value of $58,005.00. Following the completion of the transaction, the insider now owns 15,398 shares of the company’s stock, valued at approximately $595,440.66. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Dennis Mulroy sold 12,220 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $39.91, for a total transaction of $487,700.20. Following the sale, the chief financial officer now directly owns 4,744 shares in the company, valued at approximately $189,333.04. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 22,440 shares of company stock worth $892,936 over the last ninety days. Corporate insiders own 33.70% of the company’s stock.

Institutional Trading of AnaptysBio

Several hedge funds have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC acquired a new stake in AnaptysBio in the 1st quarter valued at about $38,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in AnaptysBio in the first quarter valued at approximately $265,000. Susquehanna Fundamental Investments LLC purchased a new position in AnaptysBio in the first quarter worth approximately $1,221,000. Acadian Asset Management LLC purchased a new position in AnaptysBio in the first quarter worth approximately $420,000. Finally, Platinum Investment Management Ltd. acquired a new position in AnaptysBio during the 1st quarter worth approximately $1,490,000.

AnaptysBio Trading Down 0.6 %

NASDAQ:ANAB opened at $32.03 on Wednesday. The company has a market cap of $875.03 million, a P/E ratio of -5.22 and a beta of -0.29. AnaptysBio has a twelve month low of $13.36 and a twelve month high of $41.31. The company’s 50-day moving average price is $35.45 and its 200-day moving average price is $29.72.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82). The business had revenue of $10.97 million during the quarter, compared to analysts’ expectations of $25.85 million. AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. On average, analysts expect that AnaptysBio will post -6.84 earnings per share for the current year.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.